Denifanstat + Placebo
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
MASH
Conditions
MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Trial Timeline
Mar 1, 2025 → Dec 1, 2030
NCT ID
NCT06594523About Denifanstat + Placebo
Denifanstat + Placebo is a phase 3 stage product being developed by Sagimet Biosciences for MASH. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06594523. Target conditions include MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06692283 | Phase 3 | Withdrawn |
| NCT06594523 | Phase 3 | Withdrawn |
Competing Products
6 competing products in MASH
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3849891 + Placebo | Eli Lilly | Phase 1 | 33 |
| RO7790121 | Roche | Phase 1 | 33 |
| Placebo + IBI362 | Innovent Biologics | Phase 2 | 51 |
| ALN-HSD + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Resmetirom + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |
| TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US) | Sagimet Biosciences | Phase 2 | 44 |